# Mereo BioPharma Group plc: overview MREO · Nasdaq · CIK 1719714 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/mreo.md) · [Financials](/companies/mreo/financials.md) · [Filings](/companies/mreo/filings.md) · [Insiders](/companies/mreo/insiders.md) Latest reported revenue: [$0](/filings/0001193125-26-343533.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-343533). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [0.0](/filings/0001193125-25-274272.md) | [0.0 d](/filings/0001193125-26-115226.md) | not reported | [500](/filings/0001193125-26-343533.md) | [0.0](/filings/0001193125-25-274272.md) | [0.0 d](/filings/0001193125-26-115226.md) | not reported | [0.0](/filings/0001193125-26-343533.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | [(2099.8%)](/filings/0001193125-26-343533.md) | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | [(2923.2%)](/filings/0001193125-26-343533.md) | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.02)](/filings/0001193125-25-274272.md) | not reported | [(0.02)](/filings/0001193125-26-218232.md) | [(0.02)](/filings/0001193125-26-343533.md) | [(0.01)](/filings/0001193125-25-274272.md) | not reported | [(0.01)](/filings/0001193125-26-218232.md) | [(0.01)](/filings/0001193125-26-343533.md) | | Free cash flow | $k | [(7,519) d](/filings/0001193125-25-274272.md) | [(9,420) d](/filings/0001193125-26-115226.md) | [(8,349)](/filings/0001193125-26-218232.md) | [(7,651) d](/filings/0001193125-26-343533.md) | [(7,309) d](/filings/0001193125-25-274272.md) | [(7,682) d](/filings/0001193125-26-115226.md) | [(4,312)](/filings/0001193125-26-218232.md) | [(6,043) d](/filings/0001193125-26-343533.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [36.5](/filings/0001193125-23-082264.md) | [0.0](/filings/0000950170-24-037348.md) | [10.0](/filings/0000950170-25-044787.md) | [0.0](/filings/0001193125-26-115226.md) | [0.5](/filings/0001193125-26-115226.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(57.4%)](/filings/0001193125-23-082264.md) | not reported | [(284.2%)](/filings/0000950170-25-044787.md) | not reported | [(8021.4%)](/filings/0001193125-26-115226.md) | | Net margin | % | [34.9%](/filings/0001193125-23-082264.md) | not reported | [(294.7%)](/filings/0000950170-25-044787.md) | not reported | [(8375.6%)](/filings/0001193125-26-115226.md) | | Diluted EPS | $ per share | [(0.05)](/filings/0001193125-23-082264.md) | [(0.07)](/filings/0000950170-24-037348.md) | [(0.04)](/filings/0000950170-25-044787.md) | [(0.06)](/filings/0001193125-26-115226.md) | [(0.05)](/filings/0001193125-26-115226.md) | | Free cash flow | $m | [(5.8)](/filings/0001193125-23-082264.md) | [(48.8)](/filings/0000950170-24-037348.md) | [(21.1)](/filings/0000950170-25-044787.md) | [(32.8)](/filings/0001193125-26-115226.md) | [(31.0)](/filings/0001193125-26-115226.md) | - Revenue. XBRL Revenue: ifrs-full:Revenue; Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: ifrs-full:Revenue; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue; Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent; Revenue: ifrs-full:Revenue; Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities; Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mreo/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Rubric Capital Management LP](/funds/1687509.md) | 2026-06-30 | $4.9m | 15,307,347 | | Unchanged | | [683 Capital Management, LLC](/funds/1404574.md) | 2026-06-30 | $3.7m | 11,777,856 | | Reduced −222,144 | | [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $2.6m | 8,195,281 | | Reduced −6 | | [Defilade Capital Management, L.P.](/funds/2088557.md) | 2026-06-30 | $2.4m | 7,558,756 | | Unchanged | | [Newtyn Management, LLC](/funds/1569241.md) | 2026-06-30 | $953.1k | 3,000,000 | | Reduced −4,079,056 | | [Tejara Capital Ltd](/funds/1879713.md) | 2026-06-30 | $647.3k | 2,037,520 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $460.3k | 1,447,627 | | Reduced −42,501 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $419.1k | 1,319,241 | | Added +1,131,402 | | [EcoR1 Capital, LLC](/funds/1587114.md) | 2026-06-30 | $317.7k | 1,000,000 | | Reduced −12,368,855 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $246.2k | 774,944 | | Added +634,971 | ## Recent filings [All 432 filings](/companies/mreo/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-19 | 07:52 ET | [8-K](/filings/0001193125-26-356168.md) | 3.01 Delisting notice | 0001193125-26-356168 | | 2026-08-11 | 08:37 ET | [10-Q](/filings/0001193125-26-343533.md) | Quarterly report, period 2026-06-30 | 0001193125-26-343533 | | 2026-08-11 | 08:26 ET | [8-K](/filings/0001193125-26-343519.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-343519 | | 2026-08-11 | 08:07 ET | [8-K](/filings/0001193125-26-343482.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-343482 | | 2026-05-14 | 10:22 ET | [8-K](/filings/0001193125-26-223071.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-223071 | | 2026-05-12 | 08:56 ET | [8-K/A](/filings/0001193125-26-218290.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-218290 | | 2026-05-12 | 08:03 ET | [10-Q](/filings/0001193125-26-218232.md) | Quarterly report, period 2026-03-31 | 0001193125-26-218232 | | 2026-05-12 | 07:33 ET | [8-K](/filings/0001193125-26-218192.md) | 2.01 Completion of an acquisition or disposition; 9.01 Financial statements and exhibits | 0001193125-26-218192 | | 2026-04-09 | 06:51 ET | [DEF 14A](/filings/0001193125-26-148832.md) | Proxy statement, period 2026-04-08 | 0001193125-26-148832 | | 2026-03-27 | 06:10 ET | [8-K](/filings/0001193125-26-127253.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-127253 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-115226.md), filed Mar 19, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/1ea9b173-c514-4840-a5d4-54dcbebcc9fc) ## About the filer - CIK: 1719714 - Tickers: MREO - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: X0 - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.